The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up

[
Wegovy, Zepbound, Saxenda, and other GLP-1 or GIP medications are needlessly out of reach for many Americans. Read More
https://fortune.com/img-assets/wp-content/uploads/2025/03/GettyImages-2177724858-e1741038134266.jpg?resize=1200,600
https://fortune.com/2025/03/04/ozempic-zepbound-health-care-costs-glp-1-gip-medications/


Wendy Barnes